Equities

Prenetics Global Ltd

PRE:NMQ

Prenetics Global Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.60
  • Today's Change0.17 / 3.84%
  • Shares traded12.83k
  • 1 Year change-12.38%
  • Beta-0.1811
Data delayed at least 15 minutes, as of Nov 08 2024 20:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients.

  • Revenue in USD (TTM)22.50m
  • Net income in USD-45.63m
  • Incorporated--
  • Employees320.00
  • Location
    Prenetics Global LtdUnit 701-706, K11 Atelier King's Road,728 King's Road, Quarry Bay Hong KongHKG
  • Phone+852 22109588
  • Websitehttps://ir.prenetics.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRE:NMQ since
announced
Transaction
value
Europa Sports Partners LLCDeal completed19 Aug 202419 Aug 2024Deal completed-16.06%--
Data delayed at least 15 minutes, as of Nov 08 2024 20:46 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Protara Therapeutics Inc0.00-40.69m52.40m26.00--0.5693-----3.19-3.190.004.460.00----0.00-41.35-37.02-43.70-38.29------------0.00------38.71---17.67--
Angion Biomedica Corp0.00-38.66m54.73m32.00---------4.83-4.830.00-0.1610.00----0.00-144.89-105.91-202.49-331.69-------712.81---------100.00--9.31------
Unicycive Therapeutics Inc0.00-24.41m55.67m14.00---------0.2843-0.28430.000.71930.00----0.00-68.77-218.20-118.93-609.54-------3,877.49----0.00---29.02---73.95------
Prenetics Global Ltd22.50m-45.63m56.20m320.00--0.2599--2.50-3.79-4.141.8617.700.08753.234.6370,304.00-18.52---22.89--52.31---211.67--1.98-8.670.0122--65.17--75.91------
Shattuck Labs Inc4.12m-85.28m56.32m75.00--0.5091--13.66-1.85-1.850.08832.320.029----54,986.67-60.08-29.14-66.66-32.42-----2,067.99-565.33----0.00--154.14-40.6214.37---19.15--
Immuneering Corp0.00-56.07m56.34m66.00--0.8497-----1.91-1.910.002.240.00----0.00-55.52---59.10--------------0.00---100.00---5.86------
Gain Therapeutics Inc0.00-21.60m56.56m29.00--4.73-----1.33-1.330.000.46820.00----0.00-115.33---170.44---------13,827.07----0.0396---60.6221.77-26.59--13.96--
OS Therapies Inc0.00-6.55m57.14m4.00---------0.3011-0.30110.00-1.32------0.00-------------------0.9763---------24.09------
Actinium Pharmaceuticals Inc81.00k-42.62m59.90m49.00--1.34--739.46-1.52-1.520.00291.430.0009----1,653.06-45.12-46.98-50.13-52.71-----52,620.99-6,683.95----0.0006---92.14---47.86--9.75--
Mural Oncology PLC0.00-173.30m59.97m117.00--0.2913-----10.35-10.350.0012.090.00----0.00-131.01---164.28--------------0.00-------9.29------
Enzo Biochem Inc31.91m-9.82m60.08m125.00--1.07--1.88-0.194-0.51020.62681.070.30732.347.25255,256.00-9.46-14.58-13.74-19.5645.8640.43-30.77-26.202.55--0.0047--2.72-17.0360.77---41.75--
Omega Therapeutics Inc6.31m-78.90m60.12m93.00--2.29--9.52-1.43-1.430.11450.47620.0318--6.6767,892.48-39.72---46.68-------1,249.54------0.3917--49.25--5.13------
Bioqual Inc-100.00bn-100.00bn60.37m108.00--1.63----------41.34----------8.14--9.52--19.36--7.13----0.0021.43-5.2711.79-84.12-25.261.6010.76
Precision BioSciences Inc75.10m11.48m60.62m108.0010.970.96643.860.80720.76410.052412.858.670.4729--29.70688,954.107.23-35.359.00-44.22----15.28-147.50----0.2557--94.1534.9641.67---32.01--
Data as of Nov 08 2024. Currency figures normalised to Prenetics Global Ltd's reporting currency: US Dollar USD

Institutional shareholders

10.97%Per cent of shares held by top holders
HolderShares% Held
Eastspring Investments (Singapore) Ltd.as of 30 Sep 2024427.96k4.02%
Pacific Alliance Investment Management (HK) Ltd.as of 27 Nov 2023375.29k3.53%
Nomura Securities Co., Ltd. (Private Banking)as of 30 Jun 2024322.95k3.04%
UBS Securities LLCas of 30 Jun 202440.09k0.38%
Aspire Private Capital LLCas of 30 Sep 2024114.000.00%
BofA Securities, Inc.as of 30 Jun 2024111.000.00%
Wolverine Asset Management LLCas of 30 Sep 20241.000.00%
More ▼
Data from 27 Nov 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.